Search Results for "Dipentum"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Dipentum. Results 1 to 3 of 3 total matches.
See also: mesalamine, olsalazine
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
) Maintenance: 3-6 g PO daily in divided doses 1338.00
Olsalazine – Dipentum (Meda) 250 mg caps Induction: 1.5 ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Olsalazine – Dipentum (Meda) 250 mg caps Induction: 1.5-3 g PO daily in 2 divided doses 1705.20
Maintenance ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
– Dipentum
(Meda)
250 mg caps Induction: 1.5-3 g PO daily in 2 divided doses
Maintenance: 500 mg PO bid ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction